Future perspectives in COPD

Página do item simplificado
dc.contributor.authorCelli, Bartolome
dc.contributor.authorGoldstein, Roger
dc.contributor.authorJardim, José Roberto [UNIFESP]
dc.contributor.authorKnobil, Katharine
dc.contributor.institutionTufts Univ
dc.contributor.institutionUniv Toronto
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionGlaxoSmithKline Inc
dc.date.accessioned2016-01-24T12:38:10Z
dc.date.available2016-01-24T12:38:10Z
dc.date.issued2005-12-01
dc.description.abstractThe pathophysiology of chronic obstructive pulmonary disease (COPD) is complex. the development of a multidimensional index-such as the BODE index-provides a means of classifying patients with COPD that also correlates with their prognosis. the individual components of the BODE index-body mass index (B), airflow obstruction (0) dyspnoea (D) and exercise capacity (E)-incorporate the pulmonary as well as the systemic effects seen in patients with COPD. Recent research has focussed on examining these impairments (including those of metabolism and inflammation) more carefully, and determining the effects of treatment on both the systemic and physiological aspects of COPD.Ongoing research initiatives by the public and private sector will contribute to our understanding of the disease processes underlying COPD, our understanding of the benefits associated with commonly used pharmacotherapies, as welt as laying the foundations for the development of new agents and therapeutic tools. Advances in the use of pharmacotherapy have been mirrored by research to better define the benefits associated with pulmonary rehabilitation. Many questions remain to be answered, but a comprehensive approach is now considered essential to the life-tong management of COPD, and will undoubtedly reduce the considerable socio-economic burden of COPD. (c) 2005 Elsevier B.V. All rights reserved.en
dc.description.affiliationTufts Univ, Dept Med, Caritas St Elizabeths Med Ctr, Boston, MA 02111 USA
dc.description.affiliationUniv Toronto, Fac Med, Div Resp Med, W Pk Healthcare Ctr, Toronto, ON M6M 2J5, Canada
dc.description.affiliationUniversidade Federal de São Paulo, Dept Pulm Dis, Pneumol Resp Div, BR-04023060 São Paulo, Brazil
dc.description.affiliationGlaxoSmithKline Inc, Resp Med Dev Ctr, Res Triangle Pk, NC USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Pulm Dis, Pneumol Resp Div, BR-04023060 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extentS41-S48
dc.identifierhttp://dx.doi.org/10.1016/j.rmed.2005.09.014
dc.identifier.citationRespiratory Medicine. London: W B Saunders Co Ltd, v. 99, p. S41-S48, 2005.
dc.identifier.doi10.1016/j.rmed.2005.09.014
dc.identifier.fileWOS000234110100006.pdf
dc.identifier.issn0954-6111
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/28559
dc.identifier.wosWOS:000234110100006
dc.language.isoeng
dc.publisherW B Saunders Co Ltd
dc.relation.ispartofRespiratory Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBODEen
dc.subjectCOPDen
dc.subjectfluticasone propionateen
dc.subjectinternational COPDen
dc.subjectgenetics networken
dc.subjectoxidative stressen
dc.subjectpulmonary rehabilitationen
dc.subjectsystemic inflammationen
dc.subjectsalmeterolen
dc.subjecttiotropiumen
dc.subjectTORCHen
dc.subjectUPLIFTen
dc.titleFuture perspectives in COPDen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000234110100006.pdf
Tamanho:
177 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos